Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ranolazine Clear all

Conditions: Sudden Cardiac Death, Ventricular Arrythmias
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Aspirus Heart and Vascular Institute-Research and Education; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Wausau, Wisconsin

Conditions: Severe Renal Impairment
Interventions: RANEXA; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Heart; Dysfunction Postoperative, Cardiac Surgery
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 22 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Royal Oak, Michigan • Troy, Michigan

Conditions: Chronic Angina
Interventions: Ranolazine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 29
States / cities: Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 23 more

Conditions: Stable Angina, Metabolic Syndrome
Interventions: Ranolazine, Placebo; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Peripheral Arterial Disease, Angina
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Colorado Prevention Center; Other
Eligibility: 40 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Myotonia Congenita, Paramyotonia Congenita, Myotonic Dystrophy 1
Interventions: Ranolazine; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Long QT Syndrome
Interventions: Placebo, Ranolazine; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 21 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Angina, Pulmonary Arterial Hypertension
Interventions: Ranolazine; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Ischemic Mitral Regurgitation
Interventions: Ranolazine (Active drug), Placebo; Drug
Lead sponsor: University Cardiology; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Pulmonary Hypertension
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Atrial Fibrillation
Interventions: Ranolazine, Dronedarone, Ranolazine placebo, Dronedarone placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 15
States / cities: Beverly Hills, California • Newport Beach, California • San Francisco, California + 12 more

Conditions: Microvascular Angina
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 30 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Premature Ventricular Beats
Interventions: Ranolazine; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Coronary Artery Disease, Pain, Peripheral Nervous System Diseases, Polyneuropathy
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Houma, Louisiana

Conditions: Severe Coronary Artery Disease, Ischaemic Myocardial Dysfunction
Interventions: Ranolazine; Drug
Lead sponsor: Saint Thomas Health; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pulmonary Hypertension
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Pulmonary Hypertension, Diastolic Left Ventricular Dysfunction
Interventions: Ranolazine; Drug
Lead sponsor: Boston University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: ALS
Interventions: Ranolazine 500 MG, Ranolazine 1000 MG; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Coronary Artery Disease, Angina Pectoris
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 2,651 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 86
States / cities: Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 74 more

Conditions: Angina
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: Amit Malhotra, MD; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Southaven, Mississippi

Conditions: Chronic Stable Angina
Interventions: Ranolazine, Aerobic Exercise, Placebo; Drug · Behavioral
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Angina
Interventions: Ranolazine, Sugar pill; Drug
Lead sponsor: North Florida Foundation for Research and Education; Other
Eligibility: 18 Years to 99 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Pulmonary Hypertension
Interventions: 11C-acetate, [18F]Fluoro-2-deoxy-2-D-glucose, Cardiac MRI; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction

A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine

Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery

An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)

Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome

Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease

Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1

Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients

Ranolazine and Pulmonary Hypertension

Effect of Ranolazine on Valvular Disease in Patients With Pacemakers

Targeting Right Ventricle in Pulmonary Hypertension Gilead

Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation

Ranolazine and Microvascular Angina by PET in the Emergency Department

Study to Reduce Symptoms of Premature Beats With Ranolazine

Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy

RANOLAZINE STUDY: Speckle Tracking Derived Myocardial Strain

Targeting the Right Ventricle in Pulmonary Hypertension

Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction

Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis

Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR)

Effects of Ranolazine and Exercise on Daily Physical Activity Trial

Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents

11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension